Harry J. Leonhardt has been appointed senior vice president, general counsel and chief compliance officer, Halozyme Therapeutics, Inc. He will be responsible for all legal, compliance and intellectual property matters and reports to Dr. Helen Torley, president and chief executive officer.

Mr. Leonhardt has more than 30 years of corporate legal, intellectual property, compliance, business development and M&A experience, with an extensive background in the biotechnology sector. He most recently served as senior vice president of Legal and Compliance, and corporate secretary for Amylin Pharmaceuticals, a biotech company acquired by Bristol Myers Squibb in 2012.  

“As Halozyme executes our drug development strategies and prepares for the future commercialization of our oncology pipeline, I am pleased to welcome a biotech veteran of Harry’s caliber to our management team,” said Dr. Torley. “His experience will be invaluable to our team and will help facilitate the continued growth and success of our business.”